Fluorouracil and leucovorin in advanced breast cancer

J. H. Doroshow, K. Margolin, L. Leong, S. Akman, R. Morgan, J. Raschko, G. Somlo, V. Hamasaki, E. Womack, E. Newman, C. Ahn

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

It is clear from the studies summarized above that the combination of leucovorin and 5-FU can salvage 15-20% of heavily-pretreated patients with advanced breast cancer. In previously-untreated patients, the combination generates objective responses in over one third of women with a very modest and acceptable toxicity profile. It is also clear that the addition of mitoxantrone or cisplatin to 5-FU and leucovorin produces very effective regimens, that, at least in the case of the platinum combination, may be quite active in patients who have failed therapy with an anthracycline. All of these recently-completed trials, suggest that studies currently in progress aimed at improving the biochemical modulation of the fluoropyrimidines have real promise for enhancing the therapy of patients with advanced breast cancer further.

Original languageEnglish (US)
Pages (from-to)187-193
Number of pages7
JournalAdvances in Experimental Medicine and Biology
Volume339
StatePublished - 1993

Fingerprint

Leucovorin
Fluorouracil
Breast Neoplasms
Salvaging
Mitoxantrone
Anthracyclines
Platinum
Cisplatin
Toxicity
Modulation
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Doroshow, J. H., Margolin, K., Leong, L., Akman, S., Morgan, R., Raschko, J., ... Ahn, C. (1993). Fluorouracil and leucovorin in advanced breast cancer. Advances in Experimental Medicine and Biology, 339, 187-193.

Fluorouracil and leucovorin in advanced breast cancer. / Doroshow, J. H.; Margolin, K.; Leong, L.; Akman, S.; Morgan, R.; Raschko, J.; Somlo, G.; Hamasaki, V.; Womack, E.; Newman, E.; Ahn, C.

In: Advances in Experimental Medicine and Biology, Vol. 339, 1993, p. 187-193.

Research output: Contribution to journalArticle

Doroshow, JH, Margolin, K, Leong, L, Akman, S, Morgan, R, Raschko, J, Somlo, G, Hamasaki, V, Womack, E, Newman, E & Ahn, C 1993, 'Fluorouracil and leucovorin in advanced breast cancer', Advances in Experimental Medicine and Biology, vol. 339, pp. 187-193.
Doroshow JH, Margolin K, Leong L, Akman S, Morgan R, Raschko J et al. Fluorouracil and leucovorin in advanced breast cancer. Advances in Experimental Medicine and Biology. 1993;339:187-193.
Doroshow, J. H. ; Margolin, K. ; Leong, L. ; Akman, S. ; Morgan, R. ; Raschko, J. ; Somlo, G. ; Hamasaki, V. ; Womack, E. ; Newman, E. ; Ahn, C. / Fluorouracil and leucovorin in advanced breast cancer. In: Advances in Experimental Medicine and Biology. 1993 ; Vol. 339. pp. 187-193.
@article{a0e774e216c743ed8833872e69b1ffc6,
title = "Fluorouracil and leucovorin in advanced breast cancer",
abstract = "It is clear from the studies summarized above that the combination of leucovorin and 5-FU can salvage 15-20{\%} of heavily-pretreated patients with advanced breast cancer. In previously-untreated patients, the combination generates objective responses in over one third of women with a very modest and acceptable toxicity profile. It is also clear that the addition of mitoxantrone or cisplatin to 5-FU and leucovorin produces very effective regimens, that, at least in the case of the platinum combination, may be quite active in patients who have failed therapy with an anthracycline. All of these recently-completed trials, suggest that studies currently in progress aimed at improving the biochemical modulation of the fluoropyrimidines have real promise for enhancing the therapy of patients with advanced breast cancer further.",
author = "Doroshow, {J. H.} and K. Margolin and L. Leong and S. Akman and R. Morgan and J. Raschko and G. Somlo and V. Hamasaki and E. Womack and E. Newman and C. Ahn",
year = "1993",
language = "English (US)",
volume = "339",
pages = "187--193",
journal = "Advances in Experimental Medicine and Biology",
issn = "0065-2598",
publisher = "Springer New York",

}

TY - JOUR

T1 - Fluorouracil and leucovorin in advanced breast cancer

AU - Doroshow, J. H.

AU - Margolin, K.

AU - Leong, L.

AU - Akman, S.

AU - Morgan, R.

AU - Raschko, J.

AU - Somlo, G.

AU - Hamasaki, V.

AU - Womack, E.

AU - Newman, E.

AU - Ahn, C.

PY - 1993

Y1 - 1993

N2 - It is clear from the studies summarized above that the combination of leucovorin and 5-FU can salvage 15-20% of heavily-pretreated patients with advanced breast cancer. In previously-untreated patients, the combination generates objective responses in over one third of women with a very modest and acceptable toxicity profile. It is also clear that the addition of mitoxantrone or cisplatin to 5-FU and leucovorin produces very effective regimens, that, at least in the case of the platinum combination, may be quite active in patients who have failed therapy with an anthracycline. All of these recently-completed trials, suggest that studies currently in progress aimed at improving the biochemical modulation of the fluoropyrimidines have real promise for enhancing the therapy of patients with advanced breast cancer further.

AB - It is clear from the studies summarized above that the combination of leucovorin and 5-FU can salvage 15-20% of heavily-pretreated patients with advanced breast cancer. In previously-untreated patients, the combination generates objective responses in over one third of women with a very modest and acceptable toxicity profile. It is also clear that the addition of mitoxantrone or cisplatin to 5-FU and leucovorin produces very effective regimens, that, at least in the case of the platinum combination, may be quite active in patients who have failed therapy with an anthracycline. All of these recently-completed trials, suggest that studies currently in progress aimed at improving the biochemical modulation of the fluoropyrimidines have real promise for enhancing the therapy of patients with advanced breast cancer further.

UR - http://www.scopus.com/inward/record.url?scp=0027817332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027817332&partnerID=8YFLogxK

M3 - Article

C2 - 8178716

AN - SCOPUS:0027817332

VL - 339

SP - 187

EP - 193

JO - Advances in Experimental Medicine and Biology

JF - Advances in Experimental Medicine and Biology

SN - 0065-2598

ER -